T1	intervention 66 155	recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine
T2	outcome-Measure 821 852	progression free survival (PFS)
T3	total-participants 874 877	315
T4	control 493 506	control group
T7	intervention-participants 928 931	212
T8	control-participants 950 953	103
T9	outcome 977 987	median PFS
T10	iv-cont-median 1055 1065	39.1 weeks
T11	cv-cont-median 1069 1079	14.0 weeks
T15	outcome 1158 1184	disease control rate (DCR)
T17	iv-bin-percent 1262 1267	46.7%
T18	cv-bin-percent 1271 1277	18.45%
T19	outcome 1294 1297	DCR
T20	iv-bin-percent 1302 1308	79.72%
T21	cv-bin-percent 1312 1318	45.63%
T22	outcome 1336 1360	incidence of neutropenia
T23	outcome 1362 1372	leucopenia
T24	outcome 1377 1393	erythrocytopenia
T25	outcome 1544 1562	infusion reactions
T5	outcome 1564 1598	Left ventricular ejection fraction
T6	outcome 1672 1686	cardiotoxicity
T12	outcome 1124 1153	objective response rate (ORR)
T13	outcome 1254 1257	ORR
